



ELSEVIER

Clinica Chimica Acta 286 (1999) 275-276



Author index

Volume 286 (1999)

- Ailhaud, G., Cell surface receptors, nuclear receptors and ligands that regulate adipose tissue development **286**, 181
- Assmann, G., see Cullen, P. **286**, 31
- Bernier, L., see Davignon, J. **286**, 115
- Burnett, J.R., Wilcox, L.J., Huff, M.W., Acyl coenzyme A: cholesterol acyltransferase inhibition and hepatic apolipoprotein B secretion **286**, 231
- Burrows, N.R., see Fagot-Campagna, A. **286**, 81
- Cianflone, K., see Saleh, J. **286**, 163
- Cianflone, K., see Sniderman, A.D. **286**, 7
- Cohn, J.S., see Davignon, J. **286**, 115
- Cole, D.E.C., see Langman, L.J. **286**, 63
- Connelly, P.W., The role of hepatic lipase in lipoprotein metabolism **286**, 243
- Cullen, P., Assmann, G., High risk strategies for atherosclerosis **286**, 31
- Cybulsky, M.I., Lichtman, A.H., Hajra, L., Iiyama, K., Leukocyte adhesion molecules in atherogenesis **286**, 207
- Davignon, J., Cohn, J.S., Mabile, L., Bernier, L., Apolipoprotein E and atherosclerosis: insight from animal and human studies **286**, 115
- Dhaliwal, B.S., Steinbrecher, U.P., Scavenger receptors and oxidized low density lipoproteins **286**, 191
- Dobiášová, M., Frohlich, J.J., Advances in understanding of the role of lecithin cholesterol acyltransferase (LCAT) in cholesterol transport **286**, 257
- Duriez, P., Fruchart, J.C., High-density lipoprotein subclasses and apolipoprotein A-I **286**, 97
- Fagot-Campagna, A., Burrows, N.R., Williamson, D.F., The public health epidemiology of type 2 diabetes in children and adolescents: a case study of American Indian adolescents in the Southwestern United States **286**, 81
- Francis, G.A., Perry, R.J., Targeting HDL-mediated cellular cholesterol efflux for the treatment and prevention of atherosclerosis **286**, 219
- Frohlich, J.J., see Dobiášová, M. **286**, 257
- Fruchart, J.C., see Duriez, P. **286**, 97
- Hajjar, D.P., see Nicholson, A.C. **286**, 23
- Hajra, L., see Cybulsky, M.I. **286**, 207
- Hegele, R.A., Genetic prediction of atherosclerosis: lessons from studies in native Canadian populations **286**, 47
- Huff, M.W., see Burnett, J.R. **286**, 231
- Iiyama, K., see Cybulsky, M.I. **286**, 207
- Lamarche, B., Rashid, S., Lewis, G.F., HDL metabolism in hypertriglyceridemic states: an overview **286**, 145
- Langman, L.J., Cole, D.E.C., Homocysteine: cholesterol of the 90s? **286**, 63
- Lewis, G.F., see Lamarche, B. **286**, 145
- Lichtman, A.H., see Cybulsky, M.I. **286**, 207
- Mabile, L., see Davignon, J. **286**, 115
- Nicholson, A.C., Hajjar, D.P., Herpesviruses and thrombosis: Activation of coagulation on the endothelium **286**, 23
- Perry, R.J., see Francis, G.A. **286**, 219
- Rashid, S., see Lamarche, B. **286**, 145

Saleh, J., Sniderman, A.D., Cianflone, K., Regulation of plasma fatty acid metabolism **286**, 163

Sniderman, A.D., Cianflone, K., Lipids and vascular disease: what we do and do not know **286**, 7

Sniderman, A.D., see Saleh, J. **286**, 163

Steinbrecher, U.P., see Dhaliwal, B.S. **286**, 191

Wilcox, L.J., see Burnett, J.R. **286**, 231

Williamson, D.F., see Fagot-Campagna, A. **286**, 81

Subject index

Volume 286 (1999)

-
- ACAT inhibitor**; ACAT1; ACAT2; Apolipoprotein B metabolism; Kinetics **286**, 231
- ACAT1**; ACAT2; ACAT inhibitor; Apolipoprotein B metabolism; Kinetics **286**, 231
- ACAT2**; ACAT1; ACAT inhibitor; Apolipoprotein B metabolism; Kinetics **286**, 231
- Adipose tissue development**; Cell surface receptors; Nuclear receptors; Ligands **286**, 181
- Adolescents**; Epidemiology; Public health; Type 2 diabetes; Children; Obesity **286**, 81
- Animal models**; Atherosclerosis; Apolipoprotein E; Gene polymorphism; Lipoproteins; Dyslipidemia **286**, 115
- Apo A-I**; HDL; Apo A-II; Apo A-IV; Transgenesis; Mice; Rabbit; Clinical studies **286**, 97
- Apo A-II**; HDL; Apo A-I; Apo A-IV; Transgenesis; Mice; Rabbit; Clinical studies **286**, 97
- Apo A-IV**; HDL; Apo A-I; Apo A-II; Transgenesis; Mice; Rabbit; Clinical studies **286**, 97
- Apolipoprotein A-I**; Kinetic studies; HDL cholesterol; Triglycerides; Cholesteryl ester transfer protein; Intravascular lipases **286**, 145
- Apolipoprotein B**; Coronary disease; Prevention; Risk factors for vascular disease **286**, 7
- Apolipoprotein B metabolism**; ACAT1; ACAT2; ACAT inhibitor; Kinetics **286**, 231
- Apolipoprotein E**; Atherosclerosis; Gene polymorphism; Lipoproteins; Dyslipidemia; Animal models **286**, 115
- Atherogenesis**; Homocysteine; Cardiovascular disease **286**, 63
- Atherosclerosis**; Apolipoprotein E; Gene polymorphism; Lipoproteins; Dyslipidemia; Animal models **286**, 115
- Atherosclerosis**; Diabetes; Obesity; Polygenic disease **286**, 47
- Atherosclerosis**; High density lipoprotein; HDL; Cholesterol; Cholesterol efflux; Cardioprotection **286**, 219
- Atherosclerosis**; LCAT; Structure and function; LCAT deficiency; FER_{HDL}; Reverse cholesterol transport **286**, 257
- Atherosclerosis**; Leukocytes; VCAM-1; ICAM-1; Mouse models **286**, 207
- Atherosclerosis**; Macrophages; Scavenger receptors; Oxidized LDL; Endothelial cells **286**, 191
- Cardioprotection**; High density lipoprotein; HDL; Cholesterol; Cholesterol efflux; Atherosclerosis **286**, 219
- Cardiovascular disease**; Homocysteine; Atherogenesis **286**, 63
- Cell surface receptors**; Nuclear receptors; Ligands; Adipose tissue development **286**, 181

- Children;** Epidemiology; Public health; Type 2 diabetes; Adolescents; Obesity **286, 81**
- Cholesterol;** High density lipoprotein; HDL; Cholesterol efflux; Atherosclerosis; Cardioprotection **286, 219**
- Cholesterol efflux;** High density lipoprotein; HDL; Cholesterol; Atherosclerosis; Cardioprotection **286, 219**
- Cholesteryl ester transfer protein;** Apolipoprotein A-I; Kinetic studies; HDL cholesterol; Triglycerides; Intravascular lipases **286, 145**
- Clinical studies;** HDL; Apo A-I; Apo A-II; Apo A-IV; Transgenesis; Mice; Rabbit **286, 97**
- Coagulation;** Herpesviruses; Thrombosis; Endothelium; Vascular smooth muscle cell **286, 23**
- Coronary disease;** Prevention; Apolipoprotein B; Risk factors for vascular disease **286, 7**
- Coronary heart disease;** Risk factors; Risk assessment **286, 31**
- Diabetes;** Atherosclerosis; Obesity; Polygenic disease **286, 47**
- Dyslipidemia;** Atherosclerosis; Apolipoprotein E; Gene polymorphism; Lipoproteins; Animal models **286, 115**
- Endothelial cells;** Macrophages; Scavenger receptors; Oxidized LDL; Atherosclerosis **286, 191**
- Endothelium;** Herpesviruses; Thrombosis; Coagulation; Vascular smooth muscle cell **286, 23**
- Epidemiology;** Public health; Type 2 diabetes; Children; Adolescents; Obesity **286, 81**
- FER_{HDL};** LCAT; Structure and function; LCAT deficiency; Reverse cholesterol transport; Atherosclerosis **286, 257**
- Gene polymorphism;** Atherosclerosis; Apolipoprotein E; Lipoproteins; Dyslipidemia; Animal models **286, 115**
- HDL;** Apo A-I; Apo A-II; Apo A-IV; Transgenesis; Mice; Rabbit; Clinical studies **286, 97**
- HDL;** High density lipoprotein; Cholesterol; Cholesterol efflux; Atherosclerosis; Cardioprotection **286, 219**
- HDL cholesterol;** Apolipoprotein A-I; Kinetic studies; Triglycerides; Cholesteryl ester transfer protein; Intravascular lipases **286, 145**
- Heparin;** Hepatic lipase; Lipoproteins; Lipoprotein lipase; Triglyceride; Phospholipid; Lipoprotein receptors **286, 243**
- Hepatic lipase;** Lipoproteins; Lipoprotein lipase; Triglyceride; Phospholipid; Heparin; Lipoprotein receptors **286, 243**
- Herpesviruses;** Thrombosis; Coagulation; Endothelium; Vascular smooth muscle cell **286, 23**
- High density lipoprotein;** HDL; Cholesterol; Cholesterol efflux; Atherosclerosis; Cardioprotection **286, 219**
- Homocysteine;** Atherogenesis; Cardiovascular disease **286, 63**
- ICAM-1;** Leukocytes; Atherosclerosis; VCAM-1; Mouse models **286, 207**
- Intravascular lipases;** Apolipoprotein A-I; Kinetic studies; HDL cholesterol; Triglycerides; Cholesteryl ester transfer protein **286, 145**
- Kinetic studies;** Apolipoprotein A-I; HDL cholesterol; Triglycerides; Cholesteryl ester transfer protein; Intravascular lipases **286, 145**
- Kinetics;** ACAT1; ACAT2; ACAT inhibitor; Apolipoprotein B metabolism **286, 231**
- LCAT;** Structure and function; LCAT deficiency; FER_{HDL}; Reverse cholesterol transport; Atherosclerosis **286, 257**
- LCAT deficiency;** LCAT; Structure and function; FER_{HDL}; Reverse cholesterol transport; Atherosclerosis **286, 257**
- Leukocytes;** Atherosclerosis; VCAM-1; ICAM-1; Mouse models **286, 207**
- Ligands;** Cell surface receptors; Nuclear receptors; Adipose tissue development **286, 181**
- Lipoprotein lipase;** Hepatic lipase; Lipoproteins;

- Triglyceride; Phospholipid; Heparin; Lipoprotein receptors **286, 243**
- Lipoprotein receptors**; Hepatic lipase; Lipoproteins; Lipoprotein lipase; Triglyceride; Phospholipid; Heparin **286, 243**
- Lipoproteins**; Atherosclerosis; Apolipoprotein E; Gene polymorphism; Dyslipidemia; Animal models **286, 115**
- Lipoproteins**; Hepatic lipase; Lipoprotein lipase; Triglyceride; Phospholipid; Heparin; Lipoprotein receptors **286, 243**
- Macrophages**; Scavenger receptors; Oxidized LDL; Atherosclerosis; Endothelial cells **286, 191**
- Mice**; HDL; Apo A-I; Apo A-II; Apo A-IV; Transgenesis; Rabbit; Clinical studies **286, 97**
- Mouse models**; Leukocytes; Atherosclerosis; VCAM-1; ICAM-1 **286, 207**
- Nuclear receptors**; Cell surface receptors; Ligands; Adipose tissue development **286, 181**
- Obesity**; Atherosclerosis; Diabetes; Polygenic disease **286, 47**
- Obesity**; Epidemiology; Public health; Type 2 diabetes; Children; Adolescents **286, 81**
- Oxidized LDL**; Macrophages; Scavenger receptors; Atherosclerosis; Endothelial cells **286, 191**
- Phospholipid**; Hepatic lipase; Lipoproteins; Lipoprotein lipase; Triglyceride; Heparin; Lipoprotein receptors **286, 243**
- Polygenic disease**; Atherosclerosis; Diabetes; Obesity **286, 47**
- Prevention**; Coronary disease; Apolipoprotein B; Risk factors for vascular disease **286, 7**
- Public health**; Epidemiology; Type 2 diabetes; Children; Adolescents; Obesity **286, 81**
- Rabbit**; HDL; Apo A-I; Apo A-II; Apo A-IV; Transgenesis; Mice; Clinical studies **286, 97**
- Reverse cholesterol transport**; LCAT; Structure and function; LCAT deficiency; FER_{HDL}; Atherosclerosis **286, 257**
- Risk assessment**; Coronary heart disease; Risk factors **286, 31**
- Risk factors**; Coronary heart disease; Risk assessment **286, 31**
- Risk factors for vascular disease**; Coronary disease; Prevention; Apolipoprotein B **286, 7**
- Scavenger receptors**; Macrophages; Oxidized LDL; Atherosclerosis; Endothelial cells **286, 191**
- Structure and function**; LCAT; LCAT deficiency; FER_{HDL}; Reverse cholesterol transport; Atherosclerosis **286, 257**
- Thrombosis**; Herpesviruses; Coagulation; Endothelium; Vascular smooth muscle cell **286, 23**
- Transgenesis**; HDL; Apo A-I; Apo A-II; Apo A-IV; Mice; Rabbit; Clinical studies **286, 97**
- Triglyceride**; Hepatic lipase; Lipoproteins; Lipoprotein lipase; Phospholipid; Heparin; Lipoprotein receptors **286, 243**
- Triglycerides**; Apolipoprotein A-I; Kinetic studies; HDL cholesterol; Cholesteryl ester transfer protein; Intravascular lipases **286, 145**
- Type 2 diabetes**; Epidemiology; Public health; Children; Adolescents; Obesity **286, 81**
- Vascular smooth muscle cell**; Herpesviruses; Thrombosis; Coagulation; Endothelium **286, 23**
- VCAM-1**; Leukocytes; Atherosclerosis; ICAM-1; Mouse models **286, 207**